title: Economic implications of intra-aortic balloon support for myocardial infarction with cardiogenic shock: an analysis from the IABP-SHOCK II-trial.
abstract: BACKGROUND
  The Intra-aortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial has demonstrated the safety of intra-aortic balloon (IABP) support in patients with acute myocardial infarction (AMI) complicated by cardiogenic shock, but no beneficial effect on mortality. Currently, intra-aortic balloon pumping is still the most widely used support device. However, little is known about the economic implications associated with this device.
  
  
  METHODS
  Data of 600 patients included in the IABP-SHOCK II trial (registered at ClinicalTrials.gov, NCT00491036) with follow-up at 30 days, 6 and 12 months were subjected to an economic analysis. Patients with cardiogenic shock complicating AMI were randomly assigned to IABP additionally to optimal medical therapy (OMT; n = 301) or OMT alone (n = 299) before early revascularization. Costs were calculated from the perspective of a German healthcare payer. Cost-effectiveness and cost-utility analyses were performed using quality-adjusted life years (QALY) and reduction in New York Heart Association (NYHA) and Canadian Cardiac Society (CCS) class as effectiveness measures.
  
  
  RESULTS
  There was a statistically significant difference in overall costs between the IABP (33,155 ± 14,593 <euro>) and the control group (32,538 ± 14,031 <euro>, p < 0.00001). This was predominantly attributed to the IABP costs in the IABP (760 ± 174 <euro>) versus control group (64 ± 218 <euro>, p < 0.0001) whilst the intensive care unit costs did not differ between the groups (29,177 ± 12,013 <euro> and 29,401 ± 12,063 <euro>, p = 0.82). There was no significant difference in QALY or NYHA and CCS reduction, respectively (p = n.s.).
  
  
  CONCLUSIONS
  IABP support is associated with higher healthcare costs as compared to conservative treatment regimens. Clinically, IABP support cannot generally be recommended in AMI complicated by cardiogenic shock in the absence of a mortality benefit. However, economically considering the relatively little contribution to overall costs generated by IABP therapy it may still be considered if clinical scenarios with an IABP-induced benefit may be identified in the future.
authors: Department of Cardiology and Pneumology, University Medical Center Göttingen, Georg-August University, Robert-Koch-Str. 40, 37075, Göttingen, Germany, andreas_schuster@gmx.net.
authors: Andreas
authors: A
authors: Schuster
authors: Maggie
authors: M
authors: Faulkner
authors: Uwe
authors: U
authors: Zeymer
authors: Taoufik
authors: T
authors: Ouarrak
authors: Ingo
authors: I
authors: Eitel
authors: Steffen
authors: S
authors: Desch
authors: Gerd
authors: G
authors: Hasenfuß
authors: Holger
authors: H
authors: Thiele
mesh_terms: D000328:Adult; D000368:Aged; D015897:Comorbidity; D003362:Cost-Benefit Analysis; D005260:Female; D005858:Germany / Q000453:epidemiology; D017048:Health Care Costs / Q000706:statistics & numerical data*; D006801:Humans; D007423:Intra-Aortic Balloon Pumping / Q000191:economics* / Q000401:mortality / Q000706:statistics & numerical data; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000191:economics* / Q000401:mortality / Q000601:surgery*; D012770:Shock, Cardiogenic / Q000191:economics* / Q000401:mortality / Q000601:surgery*; D016896:Treatment Outcome
references: Eur Heart J. 2009 Feb;30(4):389-90
references: 19181707
references: Am Health Drug Benefits. 2013 Mar;6(2):88-99
references: 24991349
references: Stroke. 2006 May;37(5):1179-83
references: 16574918
references: Circulation. 2003 Jun 24;107(24):2998-3002
references: 12821585
references: Ann Thorac Surg. 1996 Aug;62(2):401-8; discussion 408-9
references: 8694598
references: Circulation. 2004 Aug 3;110(5):588-636
references: 15289388
references: Clin Res Cardiol. 2009 Dec;98(12):787-95
references: 19821135
references: Value Health. 2005 Sep-Oct;8(5):521-33
references: 16176491
references: Am Heart J. 2012 Jun;163(6):938-45
references: 22709745
references: Lancet. 2013 Nov 16;382(9905):1638-45
references: 24011548
references: Vascul Pharmacol. 2014 Feb;60(2):52-6
references: 24380840
references: N Engl J Med. 2012 Oct 4;367(14):1287-96
references: 22920912
references: Eur Heart J. 2012 Oct;33(20):2569-619
references: 22922416
references: Health Policy. 1990 Dec;16(3):199-208
references: 10109801
references: J Am Coll Cardiol. 2014 Oct 7;64(14):1407-15
references: 25277608
references: Am J Cardiol. 2003 Aug 15;92(4):450-4
references: 12918526
references: J Med Econ. 2013;16(3):381-90
references: 23301850
references: Eur Heart J. 2008 Dec;29(23):2909-45
references: 19004841
references: Eur Heart J. 2014 Oct 1;35(37):2541-619
references: 25173339
references: Eur Heart J. 2009 Feb;30(4):459-68
references: 19168529
references: Circulation. 2013 Jan 29;127(4):e362-425
references: 23247304
references: JACC Cardiovasc Interv. 2014 Jun;7(6):631-40
references: 24726295
references: Clin Cardiol. 2013 Jul;36(7):407-13
references: 23595957